profit from every SEK 100 of sales.
SEK 0SEK 100
Getinge
SEK 281.60+0.57% today
+32.0% in 1 year
1-year low SEK 180.601-year high SEK 282.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 33.97 for every SEK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Getinge sold, what it kept, and what it did with the cash.
Sales went from SEK 28.3 billion in 2022 to SEK 35.0 billion in 2025, with SEK 2.26 billion of profit last year.
SalesProfit
Getinge handed back 48% of the cash it generated last year.
SEK 1.3B
Free cash flow 2025SEK 2.6B
Bought back its own shares–
Paid as dividendsSEK 1.3B
Cash vs. debtSEK 3.4B vs. SEK 10.9B
Getinge vs. similar companies
Getinge grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Getinge | 34.0× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Getinge's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 28,291 | 31,827 | 34,759 | 34,968 | |
| 13,410 | 14,495 | 16,153 | 16,654 | |
| 3,876 | 3,694 | 3,696 | 4,464 | |
| 5,704 | 5,905 | 5,310 | 6,055 | |
| 2,491 | 2,412 | 1,638 | 2,258 | |
| 9.15 | 8.86 | 6.01 | 8.29 | |
| 47.4% | 45.5% | 46.5% | 47.6% | |
| 13.7% | 11.6% | 10.6% | 12.8% | |
| 8.8% | 7.6% | 4.7% | 6.5% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 52,032 | 53,586 | 63,918 | 56,505 |
| Cash | 5,676 | 2,728 | 2,961 | 3,401 |
| Total debt | 5,824 | 8,076 | 10,727 | 10,884 |
| Total liabilities | 21,579 | 23,183 | 30,708 | 27,012 |
| 30,038 | 30,166 | 33,005 | 29,429 | |
| 272 | 272 | 272 | 272 | |
| 8.1% | 7.9% | 5.2% | 7.5% | |
| 8.3% | 8.0% | 5.0% | 7.7% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,367 | 2,957 | 4,577 | 3,949 | |
| 1,136 | 1,353 | 1,309 | 1,314 | |
| 2,231 | 1,604 | 3,268 | 2,635 | |
| Dividends paid | 1,111 | 1,181 | 1,227 | 1,267 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 34.0×
- –
- –
- 2.6×
- 2.2×
- 29.1×
- 13.9×
- 3.4%
- 2.9%
- 1.7%
Profitability
- 47.6%
- 12.8%
- 6.5%
- –
- 7.5%
- 7.2%
- –
- –
- –
- –
Growth
- +7.3%
- −3.2%
- –
- –
- +0.0%
Financial health
- 1.2×
- 0.37
- –
- 5.8×
- 1.32
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 41%of 952
Top 41%of 883
Bottom 37%of 601
Bottom 39%of 888
Top 32%of 987
1.7%of the share price, paid each year
On $1,000 invested$17a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
56.1% of its profit
Room to growStretchedMore than it earns: 48.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
43No pass
Philip Fisher
40No pass
Peter Lynch
27No pass
Joel Greenblatt
19No pass
Charlie Munger
35No pass
Terry Smith
37No pass
Questions about Getinge
Is Getinge a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Getinge AI analysis
What does Getinge do?
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It is in Medical Devices, based in Gothenburg, Sweden, with 11,754 employees.
Does Getinge pay a dividend?
Yes. At today's price the dividend is 1.7% a year, about 56% of its yearly profit. In 2025 it paid out SEK 1.27 billion in dividends.
Is Getinge stock halal?
Yes. Getinge passes our halal screen: its business is permitted and its debt is 14% of its market value, under the 30% limit. How we check
How has Getinge stock done over the past year?
Up 32.0% over the past twelve months, to SEK 281.60. It traded between SEK 180.60 and SEK 282.50, close to its high.
Who are Getinge's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Getinge's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.